A Locke Lord team led by Douglas Gray (Providence) assisted Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) in the sale of its migraine business, including NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults, and zavegepant, to Pfizer in a total deal consideration valued at approximately $13 billion. For more information, see the press release.
This marks just the latest counsel the Firm has provided to Biohaven Ltd., from startup to IPO to the exit of its migraine business in 2022, and Locke Lord looks forward to helping the company in its new therapeutic endeavors. Gray also serves as Biohaven Ltd.’s Corporate Secretary. A sampling of deals throughout the years the Firm has handled on behalf of the company include: